CANCETF / FundTema Oncology ETF
Verdicts genuinely change. Free email alert the moment CANC's does — no target price to set, unlike a price alert.
Whether this fund clears the published standards, and the filings behind that answer. The screen runs first and nothing on the trading side can override it.
Structure, momentum, positioning and levels. Separate from the Sharia verdict above, which this side never overrides.
Tema Oncology ETF ETF · Tema ETF Trust
59 holdings · as of 2026-08-31 (2.4 months ago)
NON-COMPLIANT 19.71% of portfolio weight is in non-compliant holdings, over the 5% threshold.
59 holdings, 37 matched (71% of weight). Portfolio as of 2026-08-31, filed 2026-10-30. Source: SEC Form N-PORT.
2.60% of this portfolio’s income is non-permissible — weighted across holdings, computed over 60% of portfolio weight (29 of 59 holdings). The common approach purifies that proportion of income received — dividends — not of the position’s value. We report the ratio; what to do with it is a question for your own scholar.
51.2% compliant 0.0% questionable 19.7% non-compliant 29.1% unscreened
All holdings (59)
| Holding | Status | Weight | Every methodology, and the debt ratio behind it |
|---|---|---|---|
| Revolution Medicines Inc | UNSCREENED | 6.02% | no in-house ratios for this holding |
| LLY Eli Lilly & Co | COMPLIANT | 5.15% | AAOIFI5.2% Usmani38.6% Dow Jones Islamic6.4% S&P Shariah6.9% MSCI Islamic38.6% MSCI Islamic M-Series6.9% FTSE Shariah38.6% |
| Cogent Biosciences Inc | UNSCREENED | 4.70% | no in-house ratios for this holding |
| RO.SW Roche Holding AG | COMPLIANT | 4.17% | AAOIFIpass Usmanifail Dow Jones Islamicpass S&P Shariahpass MSCI Islamicpass MSCI Islamic M-Seriespass FTSE Shariahpass |
| NVS Novartis AG | COMPLIANT | 3.79% | AAOIFI12.5% Usmani25.9% Dow Jones Islamic11.8% S&P Shariah12.6% MSCI Islamic25.9% MSCI Islamic M-Series12.6% FTSE Shariah25.9% |
| BMY Bristol-Myers Squibb Co | NON_COMPLIANT | 3.57% | AAOIFI37.3% Usmani51.1% Dow Jones Islamic42.2% S&P Shariah44.8% MSCI Islamic51.1% MSCI Islamic M-Series44.8% FTSE Shariah48.9% |
| MRK Merck & Co Inc | COMPLIANT | 3.56% | AAOIFI14.7% Usmani41.5% Dow Jones Islamic21.8% S&P Shariah20.9% MSCI Islamic41.5% MSCI Islamic M-Series20.9% FTSE Shariah41.5% |
| ABBV AbbVie Inc | COMPLIANT | 3.32% | AAOIFIpass Usmanifail Dow Jones Islamicpass S&P Shariahpass MSCI Islamicfail MSCI Islamic M-Seriespass FTSE Shariahfail |
| HALO Halozyme Therapeutics Inc | COMPLIANT | 3.19% | AAOIFI17.2% Usmani83.3% Dow Jones Islamic27.4% S&P Shariah30.4% MSCI Islamic83.3% MSCI Islamic M-Series30.4% FTSE Shariah83.3% |
| ONC BeOne Medicines Ltd | COMPLIANT | 3.18% | AAOIFI2.8% Usmani12.5% Dow Jones Islamic0.3% S&P Shariah0.3% MSCI Islamic12.5% MSCI Islamic M-Series0.3% FTSE Shariah11.7% |
| JNJ Johnson & Johnson | COMPLIANT | 3.09% | AAOIFI7.6% Usmani24.4% Dow Jones Islamic10.9% S&P Shariah11.7% MSCI Islamic24.4% MSCI Islamic M-Series11.7% FTSE Shariah24.4% |
| IMNM Immunome Inc | NON_COMPLIANT | 3.00% | AAOIFI0.2% Usmani0.8% Dow Jones Islamic0.3% S&P Shariah0.4% MSCI Islamic0.8% MSCI Islamic M-Series0.4% FTSE Shariah0.0% |
| GMAB.CO Genmab A/S | COMPLIANT | 2.88% | AAOIFIpass Usmanifail Dow Jones Islamicfail S&P Shariahpass MSCI Islamicfail MSCI Islamic M-Seriespass FTSE Shariahfail |
| CG oncology Inc | UNSCREENED | 2.76% | no in-house ratios for this holding |
| IDYA Ideaya Biosciences Inc | NON_COMPLIANT | 2.70% | AAOIFI1.0% Usmani2.4% Dow Jones Islamic1.2% S&P Shariah1.1% MSCI Islamic2.4% MSCI Islamic M-Series1.1% FTSE Shariah0.0% |
| EXEL Exelixis Inc | COMPLIANT | 2.63% | AAOIFI1.2% Usmani6.7% Dow Jones Islamic1.5% S&P Shariah1.7% MSCI Islamic6.7% MSCI Islamic M-Series1.7% FTSE Shariah0.0% |
| BBIO Bridgebio Pharma Inc | COMPLIANT | 2.33% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| AMGN Amgen Inc | COMPLIANT | 2.06% | AAOIFI24.9% Usmani59.9% Dow Jones Islamic33.6% S&P Shariah35.1% MSCI Islamic59.9% MSCI Islamic M-Series35.1% FTSE Shariah59.9% |
| Enliven Therapeutics Inc | UNSCREENED | 2.04% | no in-house ratios for this holding |
| AZN AstraZeneca PLC | COMPLIANT | 2.00% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| LEGN Legend Biotech Corp | COMPLIANT | 1.95% | AAOIFI8.8% Usmani18.4% Dow Jones Islamic2.9% S&P Shariah2.3% MSCI Islamic18.4% MSCI Islamic M-Series2.3% FTSE Shariah18.4% |
| 9688.HK Zai Lab Ltd | NON_COMPLIANT | 1.95% | AAOIFIfail Usmanifail Dow Jones Islamicfail S&P Shariahfail MSCI Islamicfail MSCI Islamic M-Seriesfail FTSE Shariahfail |
| Celcuity Inc | UNSCREENED | 1.81% | no in-house ratios for this holding |
| Erasca Inc | UNSCREENED | 1.76% | no in-house ratios for this holding |
| Relay Therapeutics Inc | UNSCREENED | 1.61% | no in-house ratios for this holding |
| IOVA Iovance Biotherapeutics Inc | COMPLIANT | 1.56% | AAOIFI1.2% Usmani5.0% Dow Jones Islamic2.9% S&P Shariah2.4% MSCI Islamic5.0% MSCI Islamic M-Series2.4% FTSE Shariah0.0% |
| ZYME Zymeworks Inc | NON_COMPLIANT | 1.54% | AAOIFI1.0% Usmani4.0% Dow Jones Islamic1.2% S&P Shariah1.5% MSCI Islamic4.0% MSCI Islamic M-Series1.5% FTSE Shariah0.0% |
| NUVB Nuvation Bio Inc | NON_COMPLIANT | 1.31% | AAOIFI10.5% Usmani33.9% Dow Jones Islamic18.7% S&P Shariah23.6% MSCI Islamic33.9% MSCI Islamic M-Series23.6% FTSE Shariah33.4% |
| URGN UroGen Pharma Ltd | NON_COMPLIANT | 1.25% | AAOIFI8.9% Usmani77.6% Dow Jones Islamic21.2% S&P Shariah25.0% MSCI Islamic75.9% MSCI Islamic M-Series25.0% FTSE Shariah74.7% |
| RCUS Arcus Biosciences Inc | COMPLIANT | 1.21% | AAOIFI4.0% Usmani12.3% Dow Jones Islamic5.6% S&P Shariah6.2% MSCI Islamic12.3% MSCI Islamic M-Series6.2% FTSE Shariah10.9% |
| Kura Oncology Inc | UNSCREENED | 1.03% | no in-house ratios for this holding |
| GILD Gilead Sciences Inc | COMPLIANT | 1.02% | AAOIFI14.4% Usmani53.2% Dow Jones Islamic18.6% S&P Shariah21.4% MSCI Islamic53.2% MSCI Islamic M-Series21.4% FTSE Shariah53.2% |
| TYRA Tyra Biosciences Inc | COMPLIANT | 1.01% | AAOIFI0.3% Usmani1.5% Dow Jones Islamic0.5% S&P Shariah0.6% MSCI Islamic1.5% MSCI Islamic M-Series0.6% FTSE Shariah0.0% |
| Summit Therapeutics Inc | UNSCREENED | 0.97% | no in-house ratios for this holding |
| CRVS Corvus Pharmaceuticals Inc | COMPLIANT | 0.95% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| NTRA Natera Inc | COMPLIANT | 0.93% | AAOIFI0.5% Usmani9.0% Dow Jones Islamic0.9% S&P Shariah1.2% MSCI Islamic9.0% MSCI Islamic M-Series1.2% FTSE Shariah3.0% |
| TNGX Tango Therapeutics Inc | NON_COMPLIANT | 0.89% | AAOIFI0.7% Usmani3.0% Dow Jones Islamic1.9% S&P Shariah2.3% MSCI Islamic3.0% MSCI Islamic M-Series2.3% FTSE Shariah0.0% |
| AnaptysBio Inc | UNSCREENED | 0.88% | no in-house ratios for this holding |
| IMTX Immatics NV | NON_COMPLIANT | 0.81% | AAOIFI0.0% Usmani0.0% Dow Jones Islamic0.0% S&P Shariah0.0% MSCI Islamic0.0% MSCI Islamic M-Series0.0% FTSE Shariah0.0% |
| Replimune Group Inc | UNSCREENED | 0.79% | no in-house ratios for this holding |
| IMCR Immunocore Holdings PLC | NON_COMPLIANT | 0.77% | AAOIFI24.8% Usmani42.8% Dow Jones Islamic29.4% S&P Shariah24.5% MSCI Islamic42.8% MSCI Islamic M-Series24.5% FTSE Shariah39.2% |
| Cullinan Therapeutics Inc | UNSCREENED | 0.69% | no in-house ratios for this holding |
| GH Guardant Health Inc | COMPLIANT | 0.66% | AAOIFI7.8% Usmani88.7% Dow Jones Islamic17.9% S&P Shariah23.1% MSCI Islamic88.7% MSCI Islamic M-Series23.1% FTSE Shariah78.6% |
| ORIC ORIC Pharmaceuticals Inc | COMPLIANT | 0.61% | AAOIFI0.3% Usmani0.8% Dow Jones Islamic0.4% S&P Shariah0.4% MSCI Islamic0.8% MSCI Islamic M-Series0.4% FTSE Shariah0.0% |
| Candel Therapeutics Inc | UNSCREENED | 0.53% | no in-house ratios for this holding |
| Syndax Pharmaceuticals Inc | UNSCREENED | 0.50% | no in-house ratios for this holding |
| JANX Janux Therapeutics Inc | NON_COMPLIANT | 0.47% | AAOIFI1.7% Usmani2.1% Dow Jones Islamic1.4% S&P Shariah1.4% MSCI Islamic2.1% MSCI Islamic M-Series1.4% FTSE Shariah0.0% |
| Inhibrx Biosciences Inc | UNSCREENED | 0.43% | no in-house ratios for this holding |
| OLMA Olema Pharmaceuticals Inc | NON_COMPLIANT | 0.41% | AAOIFI0.1% Usmani0.1% Dow Jones Islamic0.1% S&P Shariah0.1% MSCI Islamic0.1% MSCI Islamic M-Series0.1% FTSE Shariah0.0% |
| Bicara Therapeutics Inc | UNSCREENED | 0.41% | no in-house ratios for this holding |
| BridgeBio Oncology Therapeutic | UNSCREENED | 0.41% | no in-house ratios for this holding |
| CTMX CytomX Therapeutics Inc | NON_COMPLIANT | 0.38% | AAOIFI0.7% Usmani1.5% Dow Jones Islamic1.3% S&P Shariah1.8% MSCI Islamic1.5% MSCI Islamic M-Series1.8% FTSE Shariah0.0% |
| Arvinas Inc | UNSCREENED | 0.38% | no in-house ratios for this holding |
| First American Treasury Obliga | UNSCREENED | 0.38% | no in-house ratios for this holding |
| First Tracks Biotherapeutics I | UNSCREENED | 0.38% | no in-house ratios for this holding |
| MRNA Moderna Inc | NON_COMPLIANT | 0.35% | AAOIFI2.2% Usmani11.7% Dow Jones Islamic7.4% S&P Shariah5.1% MSCI Islamic11.4% MSCI Islamic M-Series5.1% FTSE Shariah5.4% |
| Adlai Nortye Group Ltd | UNSCREENED | 0.31% | no in-house ratios for this holding |
| ArriVent Biopharma Inc | UNSCREENED | 0.31% | no in-house ratios for this holding |
| 6A3A.SG Autolus Therapeutics PLC | NON_COMPLIANT | 0.30% | AAOIFIfail Usmanifail Dow Jones Islamicfail S&P Shariahfail MSCI Islamicfail MSCI Islamic M-Seriesfail FTSE Shariahfail |
The published standards disagree about this fund by 43 points of portfolio weight — 50.9% of it passes AAOIFI, 8.1% passes Usmani. Which number is yours depends on which standard you follow.
These bars are the financial-ratio result under each standard — debt, receivables and interest income. They do not screen what the business does, so a holding can pass every ratio here and still be questionable or non-compliant on activity. The blended verdict above accounts for both.
ratios pass on 50.9% ratios fail on 13.1% 36.0% not rated under AAOIFI
ratios pass on 8.1% ratios fail on 55.3% 36.7% not rated under Usmani
ratios pass on 36.7% ratios fail on 21.6% 41.7% not rated under Dow Jones Islamic
ratios pass on 39.5% ratios fail on 14.5% 46.0% not rated under S&P Shariah
ratios pass on 8.5% ratios fail on 51.1% 40.5% not rated under MSCI Islamic
ratios pass on 39.5% ratios fail on 16.1% 44.4% not rated under MSCI Islamic M-Series
ratios pass on 10.0% ratios fail on 49.6% 40.5% not rated under FTSE Shariah
37 of 59 listed holdings carry our own per-methodology verdicts (71% of weight). The rest hold a provider verdict with no methodology breakdown, and are counted as rated by none. Of those, 29 (53% of weight) also carry the underlying debt ratio; the rest show a verdict without the figure behind it.
| Non-compliant holding | Weight |
|---|---|
| BMY Bristol-Myers Squibb Co | 3.57% |
| IMNM Immunome Inc | 3.00% |
| IDYA Ideaya Biosciences Inc | 2.70% |
| 9688.HK Zai Lab Ltd | 1.95% |
| ZYME Zymeworks Inc | 1.54% |
| NUVB Nuvation Bio Inc | 1.31% |
| URGN UroGen Pharma Ltd | 1.25% |
| TNGX Tango Therapeutics Inc | 0.89% |
| IMTX Immatics NV | 0.81% |
| IMCR Immunocore Holdings PLC | 0.77% |
Methodology breakdown computing — it will appear here on its own.
Trade setup
Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.
Why this signal?
The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.
Tema Oncology ETF (CANC) is currently considered not halal (non-compliant), per our own look-through to its filed holdings. See its filed holdings and the weight breakdown below for the reasoning.
🕌 In-house Compliance Research
Computing the full ratio and business-activity breakdown for CANC — this runs off the critical path so the page paints first. It will appear here on its own.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
Price Forecast
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
Technical Summary
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Every indicator, and what it reads
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 58.90 | NEUTRAL |
| Stochastic %K (14) | 92.00 | SELL |
| CCI (20) | 136.37 | SELL |
| Williams %R (14) | -8.00 | SELL |
| MACD (12,26,9) | 0.16 | BUY |
| ROC (10) | 5.81 | BUY |
| Momentum (10) | 2.38 | BUY |
| EMA (10) | 42.06 | BUY |
| SMA (10) | 42.17 | BUY |
| EMA (20) | 41.76 | BUY |
| SMA (20) | 41.39 | BUY |
| EMA (30) | 41.68 | BUY |
| SMA (30) | 41.27 | BUY |
| EMA (50) | 41.64 | BUY |
| SMA (50) | 41.73 | BUY |
| EMA (100) | 41.12 | BUY |
| SMA (100) | 41.75 | BUY |
| EMA (200) | 39.30 | BUY |
| SMA (200) | 39.43 | BUY |
About Tema Oncology ETF
Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology. The fund is non-diversified.
Background via Yahoo Finance — informational, not part of the verdict.
Good setup, solid confluence
SMC — Top Down
Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | BULLISH | 42 |
| 🕐 1H | BULLISH | 57 |
| ⏱ 15-Min | BEARISH | 130 |
| ⏲ 5-Min | BULLISH | 234 |
Momentum & Volume
Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.
Peer Movement
How the rest of the sector moved over the same window. Context for a price move, never a cause of one.
Peer movement computing — it will appear here on its own.
Before you act on this
The questions worth asking about any verdict on this page, answered plainly.
Is a fund screened on its name?
No. HTR reads the fund's filed holdings and screens each one, then reports the result by weight. A fund marketed as Islamic still gets the same look-through as any other.
What does unrated weight mean?
It is the share of the fund whose holdings HTR cannot cover far enough to rate. It is reported as unrated rather than counted as compliant, because a holding nobody screened should not look like one that passed.
Does the issuer's board make it compliant?
It matters, and it is noted, but it does not replace the look-through. The board's judgement and the holdings screen are shown separately so you can see when they agree and when they do not.
How often is this re-screened?
When the fund files new holdings, and on a rolling basis besides. The date on the verdict above is the last time this fund was actually recomputed.
Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.
Compare with
Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.
Peer screening computing — it will appear here on its own.
Insider Activity (90d)
Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.
NO DATA 0 buys · 0 sells
COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE
The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.
NEUTRAL report date 2026-11-03 · Asset managers net 928584 (+5135)
AI Summary
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.